Just as some politicians are increasing their calls for Washington micromanagement of the Bayh-Dole law (which allows universities and federal laboratories to license federally supported inventions for commercial development) a new study shows how impressively the current decentralized, market driven system is performing.
Patients with active systemic lupus erythematosus (SLE) were able to control their disease with Benlysta (belimumab) plus standard of care (prednisone), pharmaceutical giant GSK said in announcing the results from a 10-year continuation study.
GSK presented the study’s results at the Annual European Congress of Rheumatology (EULAR 2017), held June 14-17 in Madrid.
New Enterprise Associates has closed its 16th flagship fund on $3.3 billion, per the Wall Street Journal, the largest venture vehicle ever raised.
A monumental fundraise, yes, but billion-dollar funds are nothing new for NEA—its latest vehicle also represents the firm’s seventh consecutive $1-billion-plus venture fund. In 1978, NEA closed its first fund on $16 million. The firm has gone on to garner $17 billion in committed capital across 15 funds, not including NEA 16. Here’s a look at the firm’s largest funds to date, according to the PitchBook Platform:
Despite the best cybersecurity efforts, the number of breaches in the healthcare world is remaining fairly constant, according to the latest Protenus Breach Barometer.
The Barometer is based on data provided by DataBreaches.net.
The Maryland Science Center has promoted from within to replace president and CEO Van Reiner, who will retire this year after 13 years with the Inner Harbor attraction.
Mark Potter, the organization’s vice president of development for the past six years, will assume the top spot following Reiner’s retirement in October.
A Sanofi executive discusses his company’s leadership-development programs and approach to building employee capabilities amid rapid change.
Rich Bendis, Founding President and Chief Executive Officer, BioHealth Innovation, Brian Darmody, Associate Vice President for Corporate and Foundation Relations and former Association of University Research Parks (AURP) President, and Julie Lenzer, AVP of Innovation and Economic Development at UMD engage in a discussion of the transformed university tech transfer office at the AURP BioParks 2017 conference, held in conjunction with BIO 2017 at San Diego, California.
The session was moderated by David Winwood, Associate Executive Director and Chief Business Development Officer at Pennington Biomedical Research Center at LSU, and included an earlier panel on the transformation of medical research campuses into hubs of innovation and scientific breakthroughs.
This event is a prelude to BIO 2017 in San Diego, which generated a record breaking delegation from the state of Maryland, including numerous private sector biotechnology companies based in Maryland, Ben Wu, from Maryland Department of Commerce, Tamie Howie, from the Maryland Technology Council, and biotechnology economic development representatives from across the state.
At BIO 2017 the delegation will discuss partnering opportunities with the FDA in White Oak, state financing for biotechnology companies, and presentations from Maryland’s leading biotechnology companies at the Maryland Pavilion.
Commercializing Technologies for Societal Impact
The governments of the United States of America (through the Department of State) and India (through the Department of Science & Technology) have established the United States – India Science & Technology Endowment Fund (USISTEF) for the promotion of joint activities that would lead to innovation and technopreneurship through the application of science and technology. The Endowment Fund activities are implemented and administered through the bi-national Indo-US Science and Technology Forum (IUSSTF).
The fund aims to select and financially support promising joint U.S.-India entrepreneurial initiatives that address the theme of “Commercializing Technologies for Societal Impact” through a competitive grant program.
OpGen announced today that it has signed a supply agreement with Thermo Fisher Scientific to combine its Acuitas Rapid Test for Pathogen ID with Thermo Fisher’s real-time PCR solutions.
The biotech industry remains poised for growth, EY said in its annual industry report released today, despite continuing pressure from payers to contain drug prices and an investor pullback from capital markets that helped deflate profits and slow down revenue growth for public companies last year.
“Beyond Borders: Staying the Course” observed that while biotechs will continue to pursue the prices they seek for new drugs by citing their value—either in patient outcomes or lower costs—so too will payers seek to contain those prices.
